Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis

Endocrinology

Volumn 154, Issue 7, 2013, Pages 2399-2409

  Ben Shlomo, Anat ^a   Pichurin, Oxana ^a   Khalafi, Ramtin ^a   Zhou, Cuiqi ^a   Chesnokova, Vera ^a   Ren, Song Guang ^a   Liu, Ning Ai ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; GROWTH HORMONE; MESSENGER RNA; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2; VORINOSTAT;

ACETYLATION; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DEACETYLATION; GROWTH HORMONE BLOOD LEVEL; HORMONE INHIBITION; HORMONE RELEASE; HORMONE SYNTHESIS; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; RAT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICROSCOPY, CONFOCAL; PROLACTIN; PROTEIN BINDING; RATS; RECEPTORS, SOMATOSTATIN;

EID: 84879288119     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1132     Document Type: Article

References (40)

1. Smit MJ, Vischer HF, Bakker RA, et al. Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu Rev Pharmacol Toxicol. 2007;47:53-87.
2. Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol. 2002;366:381-416. (Pubitemid 35251788)
3. Conn PM, ed. Constitutive Activity in Receptors and Other Proteins, Part A. New York, NY: Academic Press; 2010. Methods in Enzymology, vol 484.
4. Ben-Shlomo A, Pichurin O, Barshop NJ, et al. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol. 2007;21:2565-2578. (Pubitemid 47529366)
5. Ben-Shlomo A, Zhou C, Pichurin O, et al. Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol. 2009;23:337-348.
6. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198. (Pubitemid 29362641)
7. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999-1017. (Pubitemid 37540581)
8. Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21:123-133.
9. Tuggle CK, Trenkle A. Control of growth hormone synthesis. Domest Anim Endocrinol. 1996;13:1-33. (Pubitemid 2617592)
10. Tanner JW, Davis SK, McArthur NH, French JT, Welsh TH Jr. Modulation of growth hormone (GH) secretion and GH mRNA levels by GH-releasing factor, somatostatin and secretagogues in cultured bovine adenohypophysial cells. J Endocrinol. 1990;125:109-115. (Pubitemid 20129796)
11. Acunzo J, Thirion S, Roche C, et al. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res. 2008;68:10163-10170.
12. Grant M, Kumar U. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Pept. 2010;159:3-8.
13. Barinaga M, Bilezikjian LM, Vale WW, Rosenfeld MG, Evans RM. Independent effects of growth hormone releasing factor on growth hormone release and gene transcription. Nature. 1985;314:279-281. (Pubitemid 15076521)
14. Theill LE, Karin M. Transcriptional control of GH expression and anterior pituitary development. Endocr Rev. 1993;14:670-689. (Pubitemid 24016656)
15. Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends Endocrinol Metab. 2002;13:299-303. (Pubitemid 36733960)
16. Gong FY, Shi YF, Deng JY. The regulatory mechanism by which interleukin-6 stimulates GH-gene expression in rat GH3 cells. J Endocrinol. 2006;190:397-406.
17. sα as the gsp oncogene initiates chronic extracellularly regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines. Endocrinology. 2007;148:2973-2983.
18. Ho Y, Elefant F, Cooke N, Liebhaber S. A defined locus control region determinant links chromatin domain acetylation with long-range gene activation. Mol Cell. 2002;9:291-302. (Pubitemid 34195555)
19. Liu JC, Baker RE, Chow W, Sun CK, Elsholtz HP. Epigenetic mechanisms in the dopamine D2 receptor-dependent inhibition of the prolactin gene. Mol Endocrinol. 2005;19:1904-1917. (Pubitemid 41007901)
20. Ben-Shlomo A, Wawrowsky K, Melmed S. Constitutive activity of somatostatin receptor subtypes. Methods Enzymol. 2010;484:149-164.
21. Rovati GE, Capra V, Neubig RR. The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol. 2007;71:959-964. (Pubitemid 46456999)
22. Panetta R, Greenwood MT, Warszynska A, et al. Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol. 1994;45:417-427. (Pubitemid 24094930)
23. Ben-Shlomo A, Wawrowsky KA, Proekt I, et al. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem. 2005;280:24011-24021. (Pubitemid 40884889)
24. Vlotides G, Siegel E, Donangelo I,GutmanS,RenSG,MelmedS. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 2008;68:6377-6386.
25. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol. 2005;33:53-61. (Pubitemid 40127644)
26. Modesitt SC, Parsons SJ. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? Gynecol Oncol. 2010;119:351-357.
27. Mounier F, Bluet-Pajot MT, Viollet C, et al. Effects of chronic octreotide treatment on GH secretory dynamics and tumor growth in rats bearing an ectopic somatotroph (GC) tumor. J Neuroendocrinol. 1995;7:645-651.
28. Cervia D, Petrucci C, Bluet-Pajot MT, Epelbaum J, Bagnoli P. Inhibitory control of growth hormone secretion by somatostatin in rat pituitary GC cells: sst2 but not sst1 receptors are coupled to inhibition of single-cell intracellular free calcium concentrations. Neuroendocrinology. 2002;76:99-110. (Pubitemid 34914095)
29. Cervia D, Zizzari P, Pavan B, et al. Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists. Neuropharmacology. 2003;44:672-685. (Pubitemid 36369144)
30. Ho Y, Elefant F, Liebhaber SA, Cooke NE. Locus control region transcription plays an active role in long-range gene activation. Mol Cell. 2006;23:365-375. (Pubitemid 44128843)
31. Hunsaker TL, Jefferson HS, Morrison JK, Franklin AJ, Shewchuk BM. POU1F1-mediated activation of hGH-N by deoxyribonuclease I hypersensitive site II of the human growth hormone locus control region. J Mol Biol. 2012;415:29-45.
32. Ho Y, Liebhaber SA, Cooke NE. The role of the hGH locus control region in somatotrope restriction of hGH-N gene expression. Mol Endocrinol. 2011;25:877-884.
33. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349-352. (Pubitemid 27415209)
34. Lafon-Hughes L, Di Tomaso MV, Méndez-Acuña L, Martinez-Lopez W. Chromatin-remodelling mechanisms in cancer. Mutat Res. 2008;658:191-214.
35. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351-1356. (Pubitemid 46328465)
36. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol. 2011;206:13-37.
37. Yamashita S, Slanina S, Kado H, Melmed S. Autoregulation of pituitary growth hormone messenger ribonucleic acid levels in rats bearing transplantable mammosomatotrophic pituitary tumors. Endocrinology. 1986;118:915-918. (Pubitemid 16080118)
38. Ben-Shlomo A, Schmid H, Wawrowsky K, et al. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab. 2009;94:4342-4350.
39. Tannenbaum GS, Turner J, Guo F, Videau C, Epelbaum J, Beaudet A. Homologous upregulation of sst2 somatostatin receptor expression in the rat arcuate nucleus in vivo. Neuroendocrinology. 2001;74:33-42. (Pubitemid 32642077)
40. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005;2:150-157. (Pubitemid 40823166)